Focused On-demand Library for DNA (cytosine-5)-methyltransferase 3-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UJW3

UPID:

DNM3L_HUMAN

Alternative names:

Alternative UPACC:

Q9UJW3; E9PB42; Q9BUJ4

Background:

DNA (cytosine-5)-methyltransferase 3-like plays a pivotal role in DNA methylation, a critical process for genomic stability and gene expression regulation. It acts as a regulatory factor for DNA methyltransferases DNMT3A and DNMT3B, influencing DNA methylation dynamics. This protein is essential in embryonic stem cells and germ cells, where it participates in the methylation of imprinted loci and retrotransposons, safeguarding genomic integrity.

Therapeutic significance:

Understanding the role of DNA (cytosine-5)-methyltransferase 3-like could open doors to potential therapeutic strategies. Its involvement in DNA methylation processes makes it a key target for research in epigenetic therapies, particularly in diseases where DNA methylation patterns are disrupted.